reports
Kadmon Holdings Inc: 1 director bought
A director at Kadmon Holdings Inc bought 31,000 shares at 3.239USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Kadmon Highlights Recent Progress and Reports Fourth Quarter and Full ...
Kadmon Highlights Recent Progress and Reports Fourth Quarter and Full Year 2019 Financial Results NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31, 2019. “We achieved significant progress in 2019, led by positive results from the interim analysis of the pivotal trial of KD025 in cGVHD that greatly exceeded the threshold for success, achieving overall response rates of 64% and 67% with KD025 200 mg QD and 200 mg BID, respecti...
- Jonathan Moreland
SIX SIX FLAGS ENTERTAINMENT CORPORATION
LNG CHENIERE ENERGY INC.
TNAV TELENAV
SYNL SYNALLOY CORP.
SIGI SELECTIVE INSURANCE GROUP INC.
RLH RED LION HOTELS
PBF PBF ENERGY INC. CLASS A
NGL NGL ENERGY PARTNERS LP
MCD MCDONALD'S CORPORATION
LMNX LUMINEX CORP
IMMR IMMERSION CORP.
HZN HORIZON GLOBAL CORP.
GVA GRANITE CONSTRUCTION INCORPORATED
GLPI GAMING AND LEISURE PROPERTIES INC.
GABC GERMAN AMERICAN BANCORP
CALA CALITHERA BIOSCIENCES INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ATEN A10 NETWORKS INC.
ARMK ARAMARK
AKBA AKEBIA THERAPEUTICS INC.
AGRX AGILE THERAPEUTICS
UVE UNIVERSAL INSURANCE HOLDINGS INC.
ENPH ENPHASE ENERGY INC.
KMI KINDER MORGAN INC CLASS P
MGM MGM RESORTS INTERNATIONAL
PAGP PLAINS GP HOLDINGS LP CLASS A
KDMN KADMON HOLDINGS
CNBKA CENTURY BANCORP INC. CL A
GIFI GULF ISLAND FABRICATION INC.
NBLX NOBLE MIDSTREAM PARTNERS LP
CDEV CENTENNIAL RESOURCE DEVELOPMENT INC. CLASS A
ADES ADVANCED EMISSIONS SOLUTIONS
VERI VERITONE INC.
ATGE ADTALEM GLOBAL EDUCATION INC.
XM91 SMTC CORP.
MYOV MYOVANT SCIENCE
URGN UROGEN PHARMA
MVBF MVB FINANCIAL CORP
PED PEDEVCO CORP
OFG ORIENTAL FINANCIAL GROUP
KDP INC.
REPL KEURIG DR PEPPER INC.
UPWK REPLIMUNE GROUP
REZI UPWORK
AMEH RESIDEO TECHNOLOGIES
HHC INC.
FSK APOLLO MEDICAL HOLDINGS INC
ZM THE HOWARD HUGHES CORPORATION
NXTC FS KKR CAPITAL CORP
PPR ZOOM VIDEO COMMUNICATIONS
CTVA INC.
ET NEXTCURE
AVDL ING PRIME RATE TRUST
GCI CORTEVA
INC.
EXACTTARGET INC.
AVONDALE INDUSTRIES INC.
GANNETT CO. INC.
- Jonathan Moreland
MTDR MATADOR RESOURCES COMPANY
MCD MCDONALD'S CORPORATION
GVA GRANITE CONSTRUCTION INCORPORATED
DISCA DISCOVERY INC. CLASS A
CALA CALITHERA BIOSCIENCES INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ATEN A10 NETWORKS INC.
AGRX AGILE THERAPEUTICS
SAFE SAFESTORE HOLDINGS PLC
KDMN KADMON HOLDINGS
CNBKA CENTURY BANCORP INC. CL A
VERI VERITONE INC.
ATGE ADTALEM GLOBAL EDUCATION INC.
XM91 SMTC CORP.
STKL SUNOPTA
PED INC.
EYEN PEDEVCO CORP
REZI EYENOVIA INC
AMEH RESIDEO TECHNOLOGIES
PPR INC.
WORK APOLLO MEDICAL HOLDINGS INC
STLY ING PRIME RATE TRUST
SLACK TECHNOLOGIES
INC.
HG HOLDINGS
Kadmon Announces Appointment of Steven Meehan as CFO
Kadmon Announces Appointment of Steven Meehan as CFO NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced the appointment of Steven Meehan as Executive Vice President, Chief Financial Officer. Mr. Meehan, who has served as a member of the Board of Directors at Kadmon since 2017, has over 25 years of financial leadership experience spanning corporate strategy, mergers and acquisitions, capital raising and financial planning and analysis. Mr. Meehan will provide strategic leadership to Kadmon’s finance organization and will assume responsibil...
Kadmon Announces Appointment of David E. Cohen, M.D., MPH, to Board of...
Kadmon Announces Appointment of David E. Cohen, M.D., MPH, to Board of Directors NEW YORK, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced the appointment of David E. Cohen, M.D., MPH, to its Board of Directors. Dr. Cohen has held a variety of positions at the New York University School of Medicine, including as Chief of Allergy and Contact Dermatitis, Vice Chairman of Clinical Affairs, Director of Occupational and Environmental Dermatology, and the Charles C. and Dorothea E. Harris Professor of Dermatology. “David brings to Kadmon a deep understandin...
Kadmon Announces Appointment of Cynthia Schwalm to Board of Directors
Kadmon Announces Appointment of Cynthia Schwalm to Board of Directors NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced the appointment of Cynthia Schwalm to its Board of Directors. Ms. Schwalm has extensive pharmaceutical industry experience, having held management roles at Johnson & Johnson, Amgen and Eisai, and most recently served as President and CEO of Ipsen North America. “Cynthia is an accomplished pharmaceutical executive who brings strong cross-functional operational and commercialization expertise to Kadmon,” said Harlan W. Waks...
Kadmon Announces Appointment of Tasos G. Konidaris as Interim Chairman...
Kadmon Announces Appointment of Tasos G. Konidaris as Interim Chairman of the Board NEW YORK, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Tasos G. Konidaris, a member of Kadmon’s board of directors, has been appointed interim chairman, effective immediately. Mr. Konidaris has significant experience in the biotechnology industry, including serving as Executive Vice President and Chief Financial Officer of Alcresta Therapeutics, Inc. since March 2016 and as a senior advisor of Athyrium Capital Management, L.P. since September 2015. Previously, M...
Kadmon Chairman Bart M. Schwartz to Step Down from Board
Kadmon Chairman Bart M. Schwartz to Step Down from Board NEW YORK, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Bart M. Schwartz, Esq. is stepping down as director and Chairman of the Board of Directors (the “Board”) due to increasing responsibilities at his charitable commitments, including at the All Stars Project, a national youth non-profit organization where he serves as director and was recently elected chairman of its New York board, and the Police Athletic League, New York City’s largest independent youth non-profit organization, where ...
Kadmon Announces Updated Findings from Ongoing Phase 2 Clinical Trial ...
Kadmon Announces Updated Findings from Ongoing Phase 2 Clinical Trial of KD025 in cGVHD at ASH Annual Meeting NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced updated data from its ongoing Phase 2 clinical trial of KD025, its selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), in patients with previously treated chronic graft-versus-host disease (cGVHD). The updated results reaffirm data previously presented for KD025 in cGVHD, demonstrating favorable tolerability and robust and durable clinical activity, including in pati...
Kadmon Presents Data on New ROCK Inhibitor Clinical Candidate at Anti-...
Kadmon Presents Data on New ROCK Inhibitor Clinical Candidate at Anti-Fibrotic Drug Development Summit NEW YORK, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced the presentation of preclinical data supporting the therapeutic potential of Rho-associated coiled-coil kinase (ROCK) inhibition for the treatment of fibrotic diseases. The data will be presented today by Masha Poyurovsky, Ph.D., Vice President of Molecular Signaling at Kadmon, at the 2nd Annual Anti-Fibrotic Drug Development Summit in Cambridge, MA. Kadmon ROCK Inhibitor Platform in Fibro...
Kadmon Provides Business Update and Reports Third Quarter 2018 Financi...
Kadmon Provides Business Update and Reports Third Quarter 2018 Financial Results NEW YORK, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the third quarter of 2018. “We have made tremendous progress in recent months to advance development of KD025 for the treatment of cGVHD, including receipt of FDA Breakthrough Therapy Designation and the initiation of our registration study,” said Harlan W. Waksal, M.D., President and CEO at Kadmon. “We look forward to sharing updated findings from...
Kadmon to Present at the Jefferies 2018 London Healthcare Conference
Kadmon to Present at the Jefferies 2018 London Healthcare Conference NEW YORK, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the Jefferies 2018 London Healthcare Conference on Wednesday, November 14 at 8:40 a.m. GMT (3:40 a.m. ET). A live audio webcast of the presentation may be accessed on the Investors section of the Kadmon website at . A replay of the webcast will be available for 90 days. About Kadmon Holdings, Inc. Kadmon Holdings, Inc. is a fully integrated ...
Kadmon Presents New Preclinical Data on its Immuno-Oncology Fusion Pro...
Kadmon Presents New Preclinical Data on its Immuno-Oncology Fusion Protein at SITC Annual Meeting NEW YORK, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced it will present preclinical data on KD033, its anti-PD-L1/IL-15 fusion protein in development for oncology indications, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 7-11, 2018, in Washington, D.C. KD033 is a novel immunotherapy designed to stimulate an immune response directed to the tumor microenvironment. Recombinant IL-15 alone, which stimulates cancer-...
Kadmon Announces Oral Presentation on KD025 in Chronic Graft-Versus-Ho...
Kadmon Announces Oral Presentation on KD025 in Chronic Graft-Versus-Host Disease at ASH Annual Meeting NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that updated data from its ongoing Phase 2 clinical trial evaluating KD025 for the treatment of chronic graft-versus-host disease (cGVHD) have been selected for oral presentation at the 60th American Society of Hematology (ASH) Annual Meeting, to be held December 1-4, 2018, in San Diego, CA. Details of the oral presentation are outlined below. Title: KD025-208: A Phase 2a Study of KD025 for P...
Kadmon Initiates Pivotal Phase 2 Trial of KD025 in Chronic Graft-Versu...
Kadmon Initiates Pivotal Phase 2 Trial of KD025 in Chronic Graft-Versus-Host Disease NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that the first patient has been dosed in a pivotal clinical trial of KD025 in chronic graft-versus-host disease (cGVHD). The study will evaluate the efficacy and safety of KD025, Kadmon’s ROCK2 inhibitor, in adults with cGVHD who have received at least two prior lines of systemic therapy. The trial is designed to support a filing for U.S. regulatory approval of KD025. ROCKstar (KD025-213) is a Phase 2 open-labe...
Kadmon Announces CFO Transition and Other Updates
Kadmon Announces CFO Transition and Other Updates NEW YORK, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Konstantin Poukalov has notified the company of his intent to step down as Executive Vice President, Chief Financial Officer (CFO) and Principal Accounting Officer (PAO), effective immediately. Kyle Carver, the Company’s Controller, has been appointed PAO and will report directly to the Company’s President and Chief Executive Officer (CEO) while the Company searches for a new CFO. Kadmon noted that Mr. Poukalov’s decision to resign was not r...
FDA Grants Breakthrough Therapy Designation to Kadmon's KD025 for Chro...
FDA Grants Breakthrough Therapy Designation to Kadmon's KD025 for Chronic Graft-Versus-Host Disease NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KD025, the company’s ROCK2 inhibitor, for the treatment of patients with chronic graft-versus-host disease (cGVHD) after failure of two or more lines of systemic therapy. Kadmon is currently enrolling patients in a pivotal Phase 2 clinical trial of KD025 in patients with cGVHD. The FDA selectively gr...
Kadmon Provides Business Update and Reports First Quarter 2018 Financi...
NEW YORK--(BUSINESS WIRE)-- Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2018. “We have made significant progress this quarter in the development of KD025 in cGVHD, highlighted by our alignment with the FDA to commence a registrational trial in this indication,” said Harlan W. Waksal, M.D., President and CEO at Kadmon. “We continue to prioritize the development of KD025 in cGVHD and remain on track to initiate this pivotal trial this...
Kadmon Receives FDA Guidance on Pivotal Clinical Trial Design for KD02...
NEW YORK--(BUSINESS WIRE)-- Kadmon Holdings, Inc. (NYSE:KDMN) (the “Company”) today announced that it has received final minutes from a March 2018 Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the development pathway for KD025, the Company’s Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatment of chronic graft-versus-host disease (cGVHD). Based on the FDA’s guidance, Kadmon plans to initiate an open-label, two-arm, pivotal Phase 2 clinical trial to support the potential registration of K...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.